No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months

Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated. The cohort of PD patients attending our center which tackled the challenge o...

Full description

Saved in:
Bibliographic Details
Published in:BMC nephrology 2017-08, Vol.18 (1), p.278-278, Article 278
Main Authors: Pagniez, Dominique, Duhamel, Alain, Boulanger, Eric, Lessore de Sainte Foy, Celia, Beuscart, Jean-Baptiste
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis
Biological Transport - drug effects
Biological Transport - physiology
Cohort Studies
Complications and side effects
Continuous ambulatory peritoneal dialysis
Dextrose
Female
Follow-Up Studies
Glucose
Glucose exposure
Glucose Solution, Hypertonic - administration & dosage
Glucose sparing
Human health and pathology
Humans
Infection
Infections
Kidney Failure, Chronic - diagnosis
Kidney Failure, Chronic - metabolism
Kidney Failure, Chronic - therapy
Life Sciences
Male
Metabolism
Middle Aged
Nephrology
Patient outcomes
Patients
Peritoneal dialysis
Peritoneal Dialysis - methods
Peritoneal Dialysis - trends
Peritoneal equilibration test
Peritoneum
Permeability
Risk factors
Small-solute transport
Time Factors
Transplants & implants
Treatment Outcome
Urology and Nephrology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated. The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear regression for D /D ratios over time computed for each individual, and (2) a linear mixed model. In the study period, 44 patients were treated for a total of 2376 months, 2058 without hypertonic glucose. There was one episode of peritoneal infection every 18 patient-months. The mean of slopes of the linear regression for D /D ratios was found to be significantly positive (Student's test, p 
ISSN:1471-2369
1471-2369
DOI:10.1186/s12882-017-0690-7